InMed Pharmaceuticals Inc (INM)

[peedeeheenee]

Its time to play connect the dots! 


>>>Track Record

Dr. Hossain's successful financial deals based on his drug discoveries over the last 15 years include:

15) 2004: Xenon, Novartis Enter $157M Deal For Obesity Compounds

16) 2006: Xenon and Takeda Announce $75M Agreement To Develop and Commercialize XEN401 for Pain

17) 2006: Xenon Enters Into Anemia Collaboration With Roche ($7 Million for Equity, and $44 Million From Research Funding)

18) 2012: Teva inks $376M deal on Xenon pain program<<<

http://www.stockhouse.com/companies/bullboard/c.in/inmed-pharmaceuticals-inc?postid=22781425

"I KEEP six honest serving-men 
 (They taught me all I knew); 
Their names are What and Why and When  
 And How and Where and Who." 
---Kipling 



IPO Filing: Xenon Pharmaceuticals
 By Chris Lange
Sep 10, 2014 9:40 AM
????

Xenon Pharmaceuticals Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued up to $51.75 million. The company plans to list on the Nasdaq Global Market under the symbol XENE. Underwriters for the offering were initially listed as Jefferies and Wells Fargo.

Xenon is a clinical-stage biopharmaceutical company that discovers and develops differentiated therapeutics for orphan indications. The core enabling discovery platform is focused on studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. The Extreme Genetics discovery platform yielded the first approved gene therapy product in the European Union.


Pharmaceutical partners include Teva Genentech and Merck (through its affiliate, Essex Chemie). These collaborations have aggregately generated more than $140 million in non-equity funding to date, with the potential to provide more than $1.0 billion in future milestone payments, as well as royalties and co-promotion income on product sales.

The company’s most advanced product candidate is TV-45070 (formerly XEN402). Teva is currently conducting a 300-patient, randomized Phase 2b clinical trial of TV-45070 in osteoarthritis of the knee. The company is currently planning additional development of TV-45070 in neuropathic pain indications.

At the end of June 2014, Xenon has cash, cash equivalents and marketable securities of $44.7 million, which excludes an $8 million milestone payment it received in August 2014 from Genentech. Over the next 24 months, Xenon looks to potentially gain $40.5 million in milestone payments, including the $8 million from Genentech.

http://finance.yahoo.com/news/ipo-filing-xenon-pharmaceuticals-134009754.html